Liberia

in page functions
[French]
Liberia
Total population (2017) 4,730,436
Birth cohort (2017) 160,474
Surviving Infants (surviving to 1 year per year, 2017) 151,948
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 53/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 70/1000
World Bank Index, IDA (2015) 3.10
Gross Nation Income (per capita US$, 2015) 380
Co-financing group (2017) Initial self-financing
No. of districts/territories (2016) 15

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Liberia

Type of support

Approvals

2001-2021 (US$)
(18 Oct 2017)

Commitments

2001-2021 (US$)
(18 Oct 2017)

Disbursements

2000-2017 (US$)
(18 Oct 2017)

% Disbursed

(18 Oct 2017)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $44,325,105 $59,986,309 $37,662,748
Cash Support (CASHSUPP) $198,500 $223,500 $198,500 100%
Cold Chain Equipment Optimisation Platform (CCEOP) $1,200,121 $1,200,121
Ebola EPI Recovery Plan (EEPIRP) $2,811,269 $2,811,269 $2,811,269 100%
Health system strengthening (HSS 1) $3,689,254 $3,689,254 $3,689,254 100%
Health system strengthening (HSS 2) $3,240,000 $3,240,000 $3,240,000 100%
Health system strengthening (HSS 3) $7,404,796 $11,840,000
HPV Demo (NVS) $299,607 $299,607 $234,348 78%
Immunisation services support (ISS) $2,188,750 $2,188,750 $2,188,750 100%
Injection Safety Devices (NVS) $95,500 $290,000 $123,372 129%
Injection safety support (INS) $360,500 $360,500 $266,500 74%
IPV (NVS) $84,568 $84,568 $81,712 97%
Measles-Follow-up campaign (NVS) $248,500 $248,500 $258,221 104%
Measles-Follow-up campaign op.costs (OPC) $501,000 $501,000
Penta (NVS) $10,700,808 $13,261,808 $11,448,799 107%
Pneumo (NVS) $6,985,935 $12,683,935 $8,784,365 126%
Rotavirus (NVS) $1,628,941 $3,807,941 $1,561,889 96%
Vaccine Introduction Grant (VIG) $619,000 $619,000 $619,000 100%
Yellow Fever (NVS) $2,068,056 $2,636,556 $2,156,769 104%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Liberia DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 92%
M:F sex ratio at birth (2017) 1.05
Household survey: DTP3 coverage for male (2012) 69.20%
Household survey: DTP3 coverage for female (2012) 73.80%
Household survey: Last DTP3 survey (2012) 71%
% districts achieving > 80% DTP3 coverage (2016) 80%
% districts achieving < 50% DTP3 coverage (2016) 0%
MCV WHO/UNICEF estimates (2016) 80%

Breakdown of support

Non-vaccine support Vaccine support
35% 65%
$13,013,273 $24,649,475

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Liberia

20 July 2017

Sierra Leone: vaccination card

Vaccine progress in developing countries 'in danger of stalling'

New figures show an increase in measles, pneumococcal and rotavirus vaccine coverage in developing countries, but basic vaccine coverage remains unchanged at 80%.

23 May 2017

Seth Q&A 1

The Best Intervention: Gavi CEO Seth Berkley's Q&A, Part I

Ahead of Seth Berkley’s speech to the 2017 graduating class at Johns Hopkins University in Washington, DC on 23 June, Global Health published a two-part Q&A with the Gavi CEO. In this first article, Seth describes Gavi’s latest priorities, highlights the increased risk of epidemics starting in densely populated urban slums and emphasises the need to reach every child with all WHO-recommended vaccines.

12 May 2017

Ebola

Gavi stands ready to support the DR Congo in its fight against Ebola

Gavi statement of support follows official confirmation of Ebola outbreak in the Democratic Republic of the Congo (DRC).

close icon

modal window here